USE OF URINARY PROTEIN BIOMARKERS TO DISTINGUISH BETWEEN NEOPLASTIC AND NON-NEOPLASTIC DISEASE OF THE PROSTATE

摘要

The disclosure provides methods to facilitate the diagnosis of prostate cancer. In particular, the methods disclosed herein can be used to distinguish prostate cancer from benign prostatic hyperplasia. The methods comprise determining in a sample of the subject a level of one or more biomarkers selected from the group consisting of: mucin 3 (MUC3); pepsinogen 3 preproprotein (PGA3); β-2-microglobulin (β2M); PIK3IP1; uromodulin; prion protein; apolipoprotein D; WAP four-disulfide core domain protein 2; kininogen 1 variant; collagen alpha-1(III) chain; osteopontin-c (OPN-c); epidermal growth factor (beta-urogastrone); unnamed protein product (GI 158261423); cadherin-13 isoform 1 preproprotein; collagen alpha 1 chain precursor variant; ankyrin repeat domain-containing protein 11; pro-alpha 2(I) collagen; sulfatase 2 isoform b precursor; MASP-2 protein; Inositol 1,4,5-triphosphate receptor, type 2, isoform CRA_b; unnamed protein product (GI 47077082); alpha-1-acid glycoprotein 1 precursor; Zinc-alpha-2-glycoprotein precursor (ZAG); HSCARG protein, isoform CRA_b; alpha2-HS glycoprotein; and SNC66 protein, and correlating the level of the one or more biomarkers to a reference level to facilitate diagnosis of prostate cancer or BPH.

主权项

1. A method for distinguishing prostate cancer from benign prostatic hyperplasia (BPH) in a subject, the method comprising:
determining in a sample of the subject a level of one or more biomarkers selected from the group consisting of: mucin 3 (MUC3); pepsinogen 3 preproprotein (PGA3); β-2-microglobulin (β2M); PIK3IP1; uromodulin; prion protein; apolipoprotein D; WAP four-disulfide core domain protein 2; kininogen 1 variant; collagen alpha-1(III) chain; osteopontin-c (OPN-c); epidermal growth factor (beta-urogastrone); unnamed protein product (GI 158261423); cadherin-13 isoform 1 preproprotein; collagen alpha 1 chain precursor variant; ankyrin repeat domain-containing protein 11; pro-alpha 2(I) collagen; sulfatase 2 isoform b precursor; MASP-2 protein; Inositol 1,4,5-triphosphate receptor, type 2, isoform CRA_b; unnamed protein product (GI 47077082); alpha-1-acid glycoprotein 1 precursor; Zinc-alpha-2-glycoprotein precursor (ZAG); HSCARG protein, isoform CRA_b; alpha2-HS glycoprotein; andSNC66 protein, and
correlating the level of the one or more biomarkers to a reference level to facilitate diagnosis of prostate cancer or BPH.